drug
YUVIWEL
updated 3mo agoby Ascendis Pharma Inc
community read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
Trials studying YUVIWEL
- phase3A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
- phase2A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
- phase2A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
- phase2A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
News(1)
- BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indicationBioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.biospace · 7d ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that